for people ages 18 years and up (full criteria)
at UC Irvine UCLA
study started
estimated completion



The primary purpose of this study is to evaluate the safety and efficacy of ravulizumab for the treatment of participants with generalized myasthenia gravis (gMG).

Official Title

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Ravulizumab in Complement-Inhibitor-Naïve Adult Patients With Generalized Myasthenia Gravis


Generalized Myasthenia Gravis Muscle Weakness Myasthenia Gravis Ravulizumab


You can join if…

Open to people ages 18 years and up

  1. Diagnosed with Myasthenia Gravis at least 6 months (180 days) prior to the date of the Screening Visit as confirmed by specific criteria.
  2. Myasthenia Gravis Foundation of America Clinical Classification Class II to IV at screening.
  3. MG-ADL profile must be ≥ 6 at screening and randomization (Day 1).
  4. Vaccinated against meningococcal infections within 3 years prior to, or at the time of, initiating study drug to reduce the risk of meningococcal infection (N meningitidis).

You CAN'T join if...

Medical Conditions

  1. Any active or untreated thymoma. History of thymic carcinoma or thymic malignancy unless deemed cured by adequate treatment with no evidence of recurrence for ≥ 5 years before screening.
  2. History of thymectomy within the 12 months prior to screening.
  3. History of N meningitidis infection.
  4. Use of the following within the time period specified below:
  5. IV immunoglobulin within 4 weeks of randomization
  6. Use of plasma exchange within 4 weeks of randomization
  7. Use of rituximab within 6 months of screening
  8. Participants who have received previous treatment with complement inhibitors (for example, eculizumab).


  • University of California - Irvine accepting new patients
    Orange California 92868 United States
  • Olive View-UCLA Medical Center accepting new patients
    Sylmar California 91342 United States
  • Forbes Norris MDA/ALS Research Center accepting new patients
    San Francisco California 94109 United States
  • Cedars-Sinai Medical Center accepting new patients
    Los Angeles California 90048 United States


accepting new patients
Start Date
Completion Date
Alexion Pharmaceuticals
Phase 3
Study Type
Last Updated